Simple. Definitive. Illuminating.


Simple. Definitive. Illuminating.


Transforming catheter ablation of cardiac arrhythmias

LuxCath LLC is a medical technology company founded to address persistent unmet needs in the catheter ablation treatment of cardiac arrhythmias. Its breakthrough technology uses fluorescence and optics to directly view lesions during cardiac ablation procedures. Using LuxCath’s proprietary OmniView™ light-guided ablation catheter, electrophysiologists can for the first time see and assess catheter-tissue contact quality, tissue composition and lesion quality in real time during the procedure, increasing the potential for complete and effective cardiac ablation. LuxCath is a subsidiary of Allied Minds, an innovative U.S. science and technology development and commercialization company.

About Us

Executive Team

Omar Amirana, M.D.

Chief Executive Officer

Omar is a Senior Vice President for Allied Minds who currently also serves as CEO of LuxCath Previously, Omar was a partner at Oxford Bioscience Partners, a Boston-based venture capital firm, where he sourced and led the Series A investment in nFocus Neuromedical, which commercialized a catheter-based aneurysm therapy and was sold to Covidien. Omar is currently on the board of Cardiofocus (AF catheter ablation), previously served as the Vice President of Business Development at St. Jude Medical, and was also co-founder of Cardima (AF ablation; IPO) and Resolution Medical (cardiac mapping), based in Silicon Valley. Omar earned a BS in mechanical engineering from Tufts University and an MD from Eastern Virginia Medical School.

Arun Jaganathan

General Manager

Arun Jaganathan is General Manager of LuxCath and a Director at Allied Minds, where he focuses on the life sciences portfolio, including existing subsidiaries and new company formation. Arun’s background includes experience in medical devices, life science tools and drug discovery and development. Prior to joining Allied Minds, Arun was part of the corporate strategy team at Boston Scientific, where he was involved in supporting business development and strategic planning efforts, including M&A and white space market opportunity assessments. Arun also has several years of consulting experience, most recently at Fletcher Spaght Inc., where he advised small to mid-cap life sciences companies on their growth strategy.

Terry Ransbury

Chief Technology Officer

Terry has been working in product development since graduating from Duke University in 1983 with degrees in biomedical and electrical engineering. He has worked primarily on Class III (life sustaining) medical devices and their instrumentation for companies including Cordis (JNJ), Ventritex (St. Jude Medical), BioSense-Webster (JNJ), Resolution Medical, and InnerPulse. He is EP Lab Certified and has participated in over 600 human cardiac ablation procedures around the world. He is the primary inventor on many patents for medical devices.

KC Armstrong

Product Development

With nearly 20 years in product development, KC engages in all manner of electrical, software, and mechanical design, system architecture, and technical leadership, and has designed and implemented extensive circuitry and systems for medical, industrial, military, and automotive products. He wields an impressive variety of analytical and design tools, and delights in complex numerical modeling.

Cinnamon Larson, PhD

Product Development

Cinnamon has a doctorate in mechanical engineering and over 16 years product development and analysis experience. She is a technical specialist in finite element analysis for design creation, optimization, and failure detection. She has extensive experience in project management, requirement development and documentation, regulatory documentation review and development, validation and verification testing development (FEA and testing) and implementation.

Scientific Advisors

Vivek Reddy, M.D.

Director, Cardiac Arrhythmia Service

Mount Sinai Hospital & Mount Sinai Health System

Jeremy Ruskin, M.D.

Founder, Director

Cardiac Arrhythmia Service, Massachusetts General Hospital

David Haines, M.D.

Section Head Heart Rhythm

Beaumont Hospital

Pierre Jais, M.D.


L’institut de Rythmologie et Modélisation Cardiaque,
Bordeaux, France

Andrea Natale, M.D.

Executive Medical Director

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center

Narine Sarvazyan, PhD


The George Washington University School of Medicine & Health Services

Board of Directors

Jill Smith

Chief Executive Officer

Allied Minds

Omar Amirana, M.D.

Chief Executive Officer, LuxCath

SVP, Allied Minds

Mike Turner

EVP & General Counsel

Allied Minds

Rick Randall

Former Chief Executive Officer

Target Therapeutics

John Fletcher

Managing Director

Fletcher Spaght Inc.


LuxCath’s OmniView light-guided ablation catheter is the only technology that can see into tissue during cardiac ablation and assess catheter-tissue contact and lesion progression in real time. This offers electrophysiologists a simple and more definitive end point for lesion quality, increasing the potential for complete and more effective cardiac ablation.

Cardiac ablation is a well-accepted treatment option for cardiac arrhythmias, performed more than 800,000 times every year globally. Currently, electrophysiologists rely on a range of indirect surrogate end points, such as temperature, power, duration and contact force, to assess lesion quality during the cardiac ablation procedure. However, these surrogate end points have been shown to be variable and potentially unreliable, and they do not directly assess tissue response in real time. Literature has shown single procedure recurrence rates of 20 to 40 percent when ablating atrial fibrillation (AF), the most common form of arrhythmia.

The LuxCath OmniView light-guided catheter delivers and couples light into the tissue via an optical fiber embedded in the ablation catheter to assess tissue metabolic activity. The optical signal can be used to assess stability of catheter-tissue contact, tissue composition and lesion formation. The quality of these lesions is critical, as arrhythmia will recur if the lesions are not complete and uniform across the affected tissue. As lesions are formed, natural tissue fluorescence diminishes, indicating tissue destruction. This feedback mechanism allows the electrophysiologist to better assess the quality of the lesion formed. The next generation of the OmniView is orientation-independent, emitting light and seeing in all directions, allowing for optical signals at all angles of tissue contact.

Latest News

LuxCath Appoints Terry Ransbury as Chief Technology Officer

Company Also Announces Two Medtech Veteran Additions Rick Randall and John Fletcher to its Board of Directors   BOSTON – October 4, 2018 – LuxCath, LLC, a medical device company developing a novel cardiac catheter ablation technology, today announced that Terry...

read more LuxCath eyes the atrial fibrillation market

One problem with using ablation to treat atrial fibrillation is determining when the resulting lesion is sufficient to block the electric signals underlying the arrhythmia. LuxCath thinks its OmniView catheter solves the dilemma by using an optical technology to...

read more

EPLab Digest: Using Fluorescence and Optics to View Lesions During Cardiac Ablation: Interview with Dr. Vivek Reddy

In this feature interview, EP Lab Digest speaks with Vivek Y. Reddy, MD about LuxCath’s emerging technology for real-time tissue contact assessment and lesion monitoring during cardiac ablation. Dr. Reddy is the Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai.

read more

LuxCath LLC, Demonstrates Promising Results

LuxCath LLC, Demonstrates Promising Results with Optical Tissue Characterization System in Patients during Cardiac Ablation to Cure Arrhythmias; Technology Allows Cardiologists to Continuously “See” Into Heart Tissue with Light

read more

Contact Us

LuxCath LLC
100 High St., 28th Floor
Boston, MA 02110
617.419.1800 //